Quantum BioPharma Ltd. QNTM Archives

ThursdaySep 24, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated. A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved…

ThursdaySep 24, 2026 9:40 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., appointed Michael Zapolin as CEO. Zapolin’s mandate includes financing and listing Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States. Former CEO Richard Buzbuzian is assisting with the transition to a publicly listed company, which is scheduled to go effective in the next quarter. Unbuzzd markets unbuzzd(TM), a beverage designed to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. The company said…

TuesdaySep 22, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed. Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability. Quantum BioPharma's Lucid-MS candidate is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2. Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality…

FridaySep 11, 2026 9:20 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced its placement in a BioMedWire editorial examining the potential of Lucid-MS to address limitations of existing multiple sclerosis (“MS”) treatments. The editorial highlights Quantum BioPharma’s U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, the trial would mark the first time a drug based on this mechanism is tested in people…

ThursdaySep 10, 2026 10:00 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a…

TuesdaySep 08, 2026 9:10 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) was featured in BioMedWire editorial coverage highlighting FDA clearance of the company Investigational New Drug (“IND”) application to begin a randomized, double-blind, placebo-controlled phase 2 trial of Lucid-MS in people with multiple sclerosis (“MS”). Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (“PAD2”) and target demyelination rather than broadly suppressing the immune system. The editorial notes that Lucid-MS previously completed phase 1 testing in healthy volunteers, with the company reporting favorable…

MondayAug 31, 2026 12:15 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential

Disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) received a ‘Buy’ rating from Rodman & Renshaw, which initiated coverage with an $8.00 price target based on the company’s Lucid-MS drug candidate. Described as a potentially first-in-class non-immunomodulatory small molecule, Lucid-MS is being developed to address neurodegeneration and disability progression in progressive multiple sclerosis, an area where therapeutic options remain limited. The firm’s $8.00 price target reflects its valuation of Quantum BioPharma’s development pipeline. For more information on Lucid-MS, visit https://ibn.fm/8uqwL About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…

ThursdayAug 27, 2026 3:38 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on advancing innovative therapies and technologies. The company was featured in a recent article that discussed its efforts to advance Lucid-MS, an oral investigational therapy designed to inhibit demyelination and protect myelin in people with multiple sclerosis, as MS drug development increasingly expands beyond controlling inflammation toward neuroprotection and myelin preservation. Preclinical studies demonstrated myelin preservation and functional recovery in animal models, while the company’s Phase 1 program generated safety and pharmacokinetic data supporting further development. The U.S.…

WednesdayAug 19, 2026 1:00 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS around the idea that multiple sclerosis disability can progress independently of relapses, known as progression independent of relapse activity (“PIRA”). A recent article discusses chronic active, or “smoldering,” lesions and compartmentalized inflammation within the central nervous system as potential contributors to ongoing tissue damage that may not be adequately addressed by therapies focused primarily on peripheral immune activity. Lucid-MS takes a different approach by targeting myelin degradation, with the goal of preserving myelin and supporting functional recovery rather than broadly…

WednesdayAug 19, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability. Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin. Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system. The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. Multiple sclerosis (“MS”) treatment has traditionally focused on…

Site Search

Company Search

Tag: Quantum BioPharma Ltd. QNTM